Shire Reports Top-Line Results on OPUS-2

Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Useof Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease December 6, 2013 -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialtybiopharmaceutical company, today announced top-line results from OPUS-2, aPhase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution.OPUS-2 compared lifitegrast to placebo administered twice daily for 84 days (12weeks) in dry eye patients with history of active artificial tear use within 30days prior to screening. Lifitegrast met the prespecified co-primary endpointfor the patient-reported symptom of eye dryness (change in Eye Dryness Scorefrom baseline to week 12) (p-value